文献速递流行病学与生物统计真实世界研究与卫生经济

2024年非洲猴痘流行病学的演变

Evolving Epidemiology of Mpox in Africa in 2024.
PubMed 文献 · N Engl J Med · 2025-01-29

该研究分析了2022年1月1日至2024年10月30日上报非洲疾控中心的全部猴痘病例和死亡数据。2022年1月1日至2024年8月18日,12个非洲国家共报告45,652例临床诊断和实验室确诊猴痘病例,其中1,492例死亡(病死率3.3%)。2022年至2024年,每周实验室确诊病例增至2.8倍(从176例到489例),每周所有报告病例增至4.3倍(从669例到2,900例)。

要点

  • 2022年1月1日至2024年8月18日,12个非洲国家报告45,652例猴痘病例,1,492例死亡,病死率3.3%。
  • 2022年至2024年,每周实验室确诊病例从176例增至489例(2.8倍),每周所有报告病例从669例增至2,900例(4.3倍)。
  • 刚果民主共和国2024年报告非洲约88%的猴痘病例,紧急声明前有19,513例,病死率3.1%,周均591例,2023年为281例。

核心结论

  • 非洲猴痘疾病负担高,尤其是刚果民主共和国,病例数上升、病死率高且向其他原先无猴痘的非洲国家高度传播,值得国际社会更多关注。
  • 需在刚果民主共和国实施病例发现、接触者追踪、公共卫生措施和可负担疫苗等干预措施,以降低病毒全球传播风险。

研究设计与样本

  • 研究分析了2022年1月1日至2024年10月30日上报非洲疾控中心的所有临床或实验室诊断的猴痘病例和死亡数据,以识别时间变化、地理分布和流行病学趋势。

主要发现

  • 2022年1月1日至2024年8月18日,12个非洲国家共临床诊断和实验室确诊45,652例猴痘病例,其中1,492例死亡(病死率3.3%)。
  • 2022年至2024年,每周实验室确诊猴痘病例增至2.8倍(从176例到489例),每周所有报告病例(包括临床诊断)增至4.3倍(从669例到2,900例)。
  • 刚果民主共和国2024年报告非洲约88%的猴痘病例,紧急声明前有19,513例,病死率3.1%,周均591例,2023年为281例。
  • 2024年,六个非洲国家报告了首例输入性猴痘感染,布隆迪同时报告了本地传播。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For decades after the identification of mpox in humans in the Democratic Republic of Congo (DRC) in 1970, the disease was largely confined to the rural areas of Central and West Africa and thus did not garner broad attention. On August 13, 2024, mpox was declared a Public Health Emergency of Continental Security (PHECS) by the Africa Centers for Disease Control and Prevention (Africa CDC), a notice that was followed the next day by a declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization. METHODS: In this study we analyzed all mpox cases and deaths, based on clinical or laboratory diagnosis, that were reported to the Africa CDC from January 1, 2022, to October 30, 2024, to identify temporal variations, geographic distributions, and epidemiologic trends. RESULTS: From January 1, 2022, to August 18, 2024, a total of 45,652 mpox cases were clinically diagnosed and laboratory-confirmed in 12 African countries. These cases resulted in 1492 deaths (case fatality rate, 3.3%). From 2022 to 2024, weekly laboratory-confirmed mpox cases increased by a factor of 2.8 (from 176 to 489 cases), whereas all weekly reported cases (including those with a clinical diagnosis) increased by a factor of 4.3 (from 669 to 2900 cases). The DRC, which had reported approximately 88% of mpox cases in Africa in 2024, had 19,513 cases before the emergency declaration, with a case fatality rate of 3.1% - a weekly average of 591 cases as compared with 281 in 2023. In 2024, six African countries reported their first imported mpox infections, with Burundi also reporting local transmission. CONCLUSIONS: The high mpox disease burden in Africa, especially in the DRC - with a rising number of cases, high case fatality rate, and high degree of spread to other previously mpox-free African countries - is cause for increased international concern. Case detection, contact tracing, public health measures, and affordable vaccines are needed to implement interventions in the DRC to reduce the risk of global spread of the virus.

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Ndembi N, Folayan MO, Komakech A, et al. Evolving Epidemiology of Mpox in Africa in 2024. N Engl J Med. 2025. PMID: 39887004. doi:10.1056/NEJMoa2411368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。